Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00617929|
Recruitment Status : Terminated (Replaced by another protocol)
First Posted : February 18, 2008
Results First Posted : January 20, 2017
Last Update Posted : December 28, 2017
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well giving antithymocyte globulin together with clofarabine and rituximab works in treating patients after an unsuccessful stem cell transplant.
|Condition or disease||Intervention/treatment||Phase|
|Cancer||Biological: anti-thymocyte globulin Biological: rituximab Drug: clofarabine Procedure: stem cell transplantation||Phase 2|
- To determine the rate of sustained donor engraftment at 42 days and survival at 100 days post transplantation in patients treated with anti-thymocyte globulin, clofarabine, and rituximab.
- To determine incidence of treatment-related mortality at day 100 post transplantation.
- To determine incidence of neutrophil recovery by day 42 post transplantation.
- To determine survival at day 100 and 1 year post transplantation.
- To determine the proportion of patients with chimerism at day 28 post transplantation.
- To determine incidence and severity of grades II-IV acute graft-vs-host disease by day 100 post transplantation.
- Conditioning regimen: Patients receive rituximab intravenously (IV) on day -7, anti-thymocyte globulin IV over 4-6 hours on days -6 to -4, and clofarabine IV over 1 hour on days -4 to -2.
- Hematopoietic stem cell transplantation (HSCT): Patients undergo HSCT on day 0. Patients may receive umbilical cord blood, peripheral blood stem cells, or bone marrow from unrelated or related donors.
- Graft-vs-host disease (GVHD) prophylaxis: Patients receive oral cyclosporine twice daily or cyclosporine IV every 8 hours beginning on day -3 and continuing for 100 or 180 days post transplantation followed by a taper; mycophenolate mofetil IV every 8 hours beginning on day -3 and continuing for 30 days (or 7 days after engraftment with no evidence of GVHD); and filgrastim (G-CSF) IV once daily beginning on day 1 and continuing until blood counts recover.
After completion of study therapy, patients are followed on days 100, 180, and 360.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||October 2014|
|Actual Study Completion Date :||October 2015|
Experimental: Conditioning for Graft Failure
Primary or secondary graft failure after hematopoietic stem cell transplantation defined as a > 50% loss of previously best donor chimerism or less than 25% donor chimerism beyond day +42 with pancytopenia and no evidence of relapse. Patients with any diagnosis, type of donor, hematopoietic cell graft or conditioning regimen should be considered for this study. Patients receive anti-thymocyte globulin, rituximab, and clofarabine.
Biological: anti-thymocyte globulin
administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
Other Name: Thymoglobulin®
administered 375 mg/m^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
Other Name: Rituxan(R)
administered 30 mg/m^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
Other Name: CLOLAR™
Procedure: stem cell transplantation
administered on Day 0 per institutional guidelines.
- Rate of Sustained Donor Engraftment [ Time Frame: Day 42 post transplantation ]Rate of Sustained Donor Engraftment is defined as the percent of paticipants with an absolute neutrophile count (ANC) of 500 or more without a subsequent graft rejection.
- Survival at 100 Days Post Transplant [ Time Frame: Day 100 post transplantation ]Percent of patients alive from beginning of study to Day 100 post transplantation
- Treatment-related Death [ Time Frame: Day 100 post transplantation ]Percent of patients who died related to the treatment in this study.
- Time to Primary Neutrophil Engraftment [ Time Frame: Day 42 post transplantation ]Time to primary neutrophil engraftment is defined as the percent of patients with an absolute neutrophil count (ANC) of 500 or more neutrophils in a cubic millimeter of blood.
- Survival [ Time Frame: One year post transplantation ]Percent of patients alive from beginning of study to one year post transplantation
- Chimerism [ Time Frame: Day 28 post transplantation ]Occurrence of genetically distinct cell types in a single organism
- Acute Graft-vs-host Disease [ Time Frame: Day 30-100 ]Percent of patients with Acute Graft-vs-host Disease - a process where T-cells present in the donor's bone marrow at the time of transplant identify the transplant patient as "non-self' and attack the patient's skin, liver, stomach, and/or intestines.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00617929
|United States, Minnesota|
|Masonic Cancer Center at University of Minnesota|
|Minneapolis, Minnesota, United States, 55455|
|Principal Investigator:||Jakub Tolar, MD||Masonic Cancer Center, University of Minnesota|